Wunderman Thompson Partners with Tealium
22.10.2019 17:00:00 EEST | Business Wire | Press release
Tealium, the trusted leader in real-time customer data orchestration, today announces a partnership with Wunderman Thompson, a WPP company, to integrate Tealium’s AudienceStream CDP as the Profile Streaming Engine for its Customer Cloud.
Wunderman Thompson’s Customer Cloud brings brands and people together for relevant and timely conversations, acting as the hub and clearinghouse for customer data. This platform integrates a brand’s Adtech, Martech, and other data ecosystems to create, manage, enhance, enrich, update, syndicate and activate a comprehensive profile of their customers. This innovation powers relevant and personalised experiences whenever and wherever those experiences occur, driving deeper engagement, action and higher conversions. Tealium AudienceStream CDP serves as the neutral layer of the profiles within the technology stack, syndicating and updating an enriched single view of the customer across all touchpoints, allowing experiences to be informed with the latest and best information.
“We’re excited to partner with Tealium because the technology allows us to update and syndicate consumer profiles in real time across the Adtech ecosystems, empowering our clients to deploy powerful experiences for their customers,” said Jacques van Niekerk, CEO of Wunderman Thompson Data. “With Tealium, our Customer Cloud is able to connect to the browser, ingest signals, identify the customer, update their profile, and act on this information with just the right content for the micro-moment, all within milliseconds.”
“Wunderman Thompson is on the cutting edge of data-driven engagement, so we are proud to serve as the customer data orchestration layer enabling relevant, personalised experiences for their clients,” said Mike Anderson, Founder and CTO of Tealium. “We look forward to seeing the impact our integration makes with Wunderman Thompson’s Customer Cloud and how that ultimately helps Wunderman Thompson clients deliver incredible customer experiences.”
In addition to Tealium’s AudienceStream CDP, Tealium offers a complete portfolio of solutions within Tealium’s Universal Data Hub, which includes Tealium iQ Tag Management, EventStream (API Hub) and DataAccess. Tealium also offers a Consent Management solution for addressing GDPR and CCPA requirements and pre-built connectors to hundreds of digital data sources.
To learn more about Tealium’s solutions, visit www.tealium.com.
About Tealium
Tealium revolutionises today’s digital businesses with a universal approach to customer data orchestration – spanning web, mobile, offline and Internet of Things devices. With the power to unify customer data into a single source of truth, Tealium offers a turnkey integration ecosystem supporting more than 1,200 client-side and server-side vendors and technologies. The Tealium Universal Data Hub encompasses tag management, API hub, customer data platform, and data management solutions that enable organisations to leverage real-time data to create richer, more personalised digital experiences across every team, technology, and customer touchpoint.
For more information, visit www.tealium.com.
About Wunderman Thompson
Wunderman Thompson is a creative, data and technology agency built to inspire growth for its clients and people. Our experts deliver end-to-end solutions at a global scale with an entrepreneurial spirit that infuses creativity with emerging technology to deliver revolutionary work. Headquartered in New York, we are a worldwide agency bringing together over 20,000 people in 90 markets across the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005725/en/
Contact information
Beki Hayler
Account Manager, GingerMay
beki.hayler@teamgingermay.com
T: +44 (0)203 642 1124
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom